Oral Presentations
- OP01 Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn’s disease
- OP02 Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximab
- OP03 Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn’s disease patients: The EPIC-CD study
- OP04 Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patients
- OP05 High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis
- OP06 Multiomic interrogation of the epithelium in active Ulcerative Colitis reveals dysregulated myeloid cells associated with non-response to anti-Tumour Necrosis Factor therapy.
- OP09 Long-term Colectomy rates of Ulcerative Colitis over 40-year of Different Therapeutic eras – Results from a Western Hungarian Population-based Inception Cohort between 1977–2020
- OP10 Proctocolectomy with permanent ileostomy is associated with better transplant-free survival in patients with primary sclerosing cholangitis: a retrospective cohort study
- OP11 Ileocecal resection for recently diagnosed ileocecal Crohn’s disease is associated with improved long-term outcomes compared to anti-tumor necrosis factor therapy: a population-based study.
- OP12 does early initiation of biologics change the natural history of IBD? a nationwide study from the epi-IIRN
- OP13 Postoperative Crohn’s disease recurrence: unanswered questions and future directions in diagnosis, pathophysiology, prevention and treatment. Conclusions from the 8th ECCO Scientific workshop.
- OP14 Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO
- OP15 Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extension
- OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics
- OP17 Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional Therapies
- OP18 Disease course of Crohn’s disease during the first ten years following diagnosis in a prospective European population-based inception cohort – the Epi-IBD cohort
- OP19 Gaps between ECCO quality standards of care and the real world: the E-QUALITY survey
- OP20 The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results
- OP23 Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia
- OP24 Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort stu
- OP25 Prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative data
- OP26 Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trial
- OP27 Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCU
- OP28 Children and young adults with inflammatory bowel disease have an increased incidence and risk of developing mental health conditions: a UK population-based cohort study
- OP29 Peri-natal exposure to parental Crohn’s disease is associated with impaired gut barrier, microbiome composition differences and increased risk of Crohn’s disease
- OP30 Human umbilical cord mesenchymal stem cells derived exosomes alleviate Ulcerative Colitis by inhibiting macrophage ferroptosis via miR-23b-3p/Nrf2 pathway
- OP31 High fat diet exacerbates colitis through microbial metabolite deoxycholic acids induced-ferroptosis
- OP32 The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo
- OP33 Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO)
- OP34 Enteral Nutrition Compared with Steroids in Children with Crohn’s Disease – In Israel: a nationwide study from the epi-IIRN
- OP35 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study
- OP36 Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study
- OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)
- OP38 Modulation of the septin cytoskeleton ameliorates intestinal fibrogenesis
- OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC
- OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results